UK Trials First Norovirus Vaccine Targeting Major Strains

The UK is leading a groundbreaking trial for the world's first norovirus vaccine, developed by Moderna using mRNA technology, to ease the winter strain on the NHS and prevent widespread infections. The vaccine targets three major norovirus strains and is being tested at 27 NHS sites with 2,500 participants, aiming for potential public rollout by 2026 if successful. Health Secretary Wes Streeting highlights the initiative's potential to save taxpayers millions and shift focus from sickness to prevention. Norovirus causes 12,000 hospital admissions annually in the UK and is a highly contagious gastrointestinal virus affecting millions globally. The trial will monitor participants over 25 months, with an emphasis on recruiting individuals over 60, who are more vulnerable. This initiative marks a significant step in the UK's life sciences sector, providing a hopeful shift to proactive healthcare management.